These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 7565956)

  • 41. [Indications and successes of conservative therapy in gastroenterology: peptic ulcer].
    Gugler R
    Z Gastroenterol Verh; 1989 Jul; 24():82-4. PubMed ID: 2474995
    [No Abstract]   [Full Text] [Related]  

  • 42. The medical management of reflux esophagitis. Role of antacids and acid inhibition.
    Sontag SJ
    Gastroenterol Clin North Am; 1990 Sep; 19(3):683-712. PubMed ID: 1977703
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Therapy of peptic ulcer. H2 receptor blockers].
    Domschke W
    Verh Dtsch Ges Inn Med; 1988; 94():272-5. PubMed ID: 2905101
    [No Abstract]   [Full Text] [Related]  

  • 44. Medical therapy of extraesophageal gastroesophageal reflux disease.
    Katz PO
    J Clin Gastroenterol; 2000 Apr; 30(3 Suppl):S42-4. PubMed ID: 10777172
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Factors predicting relapse during maintenance treatment with famotidine in patients with healed reflux esophagitis. Dutch Esophagitis Study Group.
    Wesdorp IC; Dekker W; Festen HP
    Clin Ther; 1997; 19(5):1048-57. PubMed ID: 9385492
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Administration of H2 receptor antagonist with proton pump inhibitor is effective for long-term control of refractory reflux esophagitis.
    Adachi K; Komazawa Y; Mihara T; Fujishiro H; Ishihara S; Amano Y; Kinoshita Y
    J Clin Gastroenterol; 2004 Mar; 38(3):297-8. PubMed ID: 15128081
    [No Abstract]   [Full Text] [Related]  

  • 47. [Gastroduodenal ulcer--changes in surgical therapy by long-term drug treatment].
    Peitsch W
    Zentralbl Chir; 1986; 111(23):1433-40. PubMed ID: 2881413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Healing, relapse rates and prophylaxis of reflux esophagitis.
    Glise H
    Scand J Gastroenterol Suppl; 1989; 156():57-64. PubMed ID: 2568016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Maintenance therapies for reflux esophagitis.
    Grey MR
    N Engl J Med; 1996 Feb; 334(9):600-1. PubMed ID: 8569838
    [No Abstract]   [Full Text] [Related]  

  • 50. Hiatus hernia and reflux esophagitis.
    Spiro HM
    Hosp Pract (Off Ed); 1994 Jan; 29(1):51-4, 61, 65-6. PubMed ID: 7904609
    [No Abstract]   [Full Text] [Related]  

  • 51. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Treatment of gastroesophageal reflux: the role of proton pump inhibitors.
    Schulman MI; Orlando RC
    Adv Intern Med; 1995; 40():273-302. PubMed ID: 7747649
    [No Abstract]   [Full Text] [Related]  

  • 53. H2-receptor antagonists.
    Nurs Times; 2004 Nov 2-8; 100(44):33. PubMed ID: 15552489
    [No Abstract]   [Full Text] [Related]  

  • 54. [Guidelines for good practice: anti-ulcer agents, indications in the adult. French Agency for Health Safety of Health Products].
    Therapie; 1999; 54(5):509-17. PubMed ID: 10667082
    [No Abstract]   [Full Text] [Related]  

  • 55. Medical management of esophageal reflux.
    Hirschowitz BI
    Yale J Biol Med; 1994; 67(3-4):223-31. PubMed ID: 7502531
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Clinical aspects of Kvamatel (famotidine) administration].
    Golochevskaia VS
    Klin Med (Mosk); 1996; 74(1):45-7. PubMed ID: 8649009
    [No Abstract]   [Full Text] [Related]  

  • 57. Meta-analysis of the effect of placebo on the outcome of medically treated reflux esophagitis.
    Pace F; Maconi G; Molteni P; Minguzzi M; Bianchi Porro G
    Scand J Gastroenterol; 1995 Feb; 30(2):101-5. PubMed ID: 7732329
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Over the counter sales of histamine-2 receptor antagonists.
    Petersen H
    Scand J Gastroenterol Suppl; 1988; 155():20-2. PubMed ID: 2907682
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of severe reflux esophagitis.
    Richter JE
    Ann Intern Med; 1986 Apr; 104(4):588-9. PubMed ID: 2869728
    [No Abstract]   [Full Text] [Related]  

  • 60. Is body mass index really the most important factor determining the healing of reflux esophagitis by esomeprazole?
    Lo GH
    Am J Gastroenterol; 2009 Mar; 104(3):787; author reply 787-8. PubMed ID: 19240701
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.